MSH3 mutation
|
Gastric Cancer
|
MSH3 mutation
|
Gastric Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
MSH3 mutation
|
Gastric Cancer
|
MSH3 mutation
|
Gastric Cancer
|
CP-675206 Sensitive: C2 – Inclusion Criteria
|
CP-675206 Sensitive: C2 – Inclusion Criteria
|
MSH3 mutation
|
CRC
|
MSH3 mutation
|
CRC
|
PARP inhibitor Resistant: D – Preclinical
|
PARP inhibitor Resistant: D – Preclinical
|
MSH3 mutation
|
CRC
|
MSH3 mutation
|
CRC
|
KU-0060648 Sensitive: D – Preclinical
|
KU-0060648 Sensitive: D – Preclinical
|